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To determine whether steroid avoidance in pediatric
kidney transplantation is safe and efficacious, a ran-
domized, multicenter trial was performed in 12 pe-
diatric kidney transplant centers. One hundred thirty
children receiving primary kidney transplants were ran-
domized to steroid-free (SF) or steroid-based (SB) im-
munosuppression, with concomitant tacrolimus, my-
cophenolate and standard dose daclizumab (SB group)
or extended dose daclizumab (SF group). Follow-up
was 3 years posttransplant. Standardized height Z-
score change after 3 years follow-up was –0.99 ± 2.20
in SF versus –0.93 ± 1.11 in SB; p = 0.825. In sub-
group analysis, recipients under 5 years of age showed
improved linear growth with SF compared to SB treat-
ment (change in standardized height Z-score at 3 years
–0.43 ± 1.15 vs. –1.07 ± 1.14; p = 0.019). There were
no differences in the rates of biopsy-proven acute re-
jection at 3 years after transplantation (16.7% in SF vs.
17.1% in SB; p = 0.94). Patient survival was 100% in
both arms; graft survival was 95% in the SF and 90%
in the SB arms (p = 0.30) at 3 years follow-up. Over the
3 year follow-up period, the SF group showed lower
systolic BP (p = 0.017) and lower cholesterol levels
(p = 0.034). In conclusion, complete steroid avoidance
is safe and effective in unsensitized children receiving
primary kidney transplants.
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Introduction
Corticosteroids have been the cornerstone of maintenance
immunosuppression therapy in pediatric renal transplanta-
tion over the last half century (1). Unfortunately, steroid
use is a two-edged sword, with side effects that are par-
ticularly serious for children, including growth retardation
with reduced final adult height (2,3), body disfigurement
(often leading to medication nonadherence), hypertension,
hyperlipidemia, diabetes mellitus, acne, osteopenia and in-
creased infection risk (4,5).
Early attempts at steroid withdrawal in renal transplant re-
cipients were associated with high rates of subsequent
acute rejection (6,7), leading to the belief that chronic
steroid usage resulted in immune dependence (5,8–11).
More recent trials of steroid withdrawal or avoidance
in adult recipients, who received induction therapy and
more powerful maintenance therapy, have shown vari-
able results. Some analyses have shown an increased
acute rejection risk (12–14), while others have not (15,16).
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Meta-analyses have demonstrated that steroid avoidance
and steroid withdrawal strategies in kidney transplantation
are not associated with increased mortality or graft loss,
despite an increase in acute rejection (17–20).
In pediatric transplantation, it is possible to withdraw
(21) or avoid steroids (22) if other immunosuppressive
agents are given in large doses (18). However, such a
strategy could induce a state of overimmunosuppression
with an increased risk of such complications as post-
transplant lymphoproliferative disorder (23). A steroid-free
(SF) protocol for pediatric kidney transplant recipients
was developed at Stanford University. This protocol re-
placed steroids with extended daclizumab induction for
the first 6 months after transplantation, followed by a
two-drug tacrolimus and mycophenolate mofetil mainte-
nance immunosuppression protocol (24,25). At the single-
center level, in comparison to a historical matched co-
hort, this protocol was associated with improved linear
growth, reduced hypertension and hyperlipidemia, with-
out an associated increase in acute rejection (24,25). Other
single-center studies confirmed these findings (26). How-
ever, the studies were not prospective and included few
African-American recipients, a traditionally high risk group.
We therefore conducted a 3 year prospective, random-
ized, multi-center study of steroid-avoidance versus stan-
dard steroid-based (SB) immunosuppression in children
receiving primary kidney transplants between 2004 and
2006.
Materials and Methods
Study design and patients
Pediatric subjects, age 0 to 21 years, who received a primary kidney trans-
plant from a deceased or living donor, were enrolled following IRB approval,
informed consent and, where appropriate, patient assent. This multi-center
study used a randomized, open-label, parallel group design. Treatment with
steroids within the 6 months prior to transplantation, en bloc kidney trans-
plantation, high panel reactive antibody (PRA) levels (>20%), pregnancy,
transplantation of a solid organ or bone marrow or hematopoietic stem cell
transplant in addition to a kidney, HIV positivity/AIDS, hypersensitivity to
tacrolimus, mycophenolate mofetil (MMF), prednisone, Cremophor, HCO-
60, or murine products, and the inability to measure height accurately were
exclusion criteria. Donor kidney exclusion criteria included donor age >55
years, kidney donation after cardiac death, cold ischemia time >20 h for
simple cold storage, and expected maximum cold ischemia time >30 h for
perfusion preservation.
Subjects were randomized (1:1) to a traditional low-dose SB immuno-
suppression regimen (steroids, standard daclizumab induction until the
second month posttransplant, and maintenance immunosuppression
with tacrolimus (Prograf R©, Astellas Pharma, Tokyo, Japan) and MMF
(CellCept R©, Hoffman-La Roche, Basel, Switzerland) or a SF immunosup-
pression regimen (prolonged daclizumab induction until the sixth month
posttransplant, tacrolimus and MMF). For both the SF arm and the SB
arm, oral tacrolimus was administered from immediately preoperatively
to recipients >5 years of age at a starting dose of 0.1 mg/kg/dose BID
for living donor recipients and 0.1 mg/kg/dose QD for deceased donor
recipients. Recipients <5 years of age received tacrolimus from imme-
diately preoperatively at 0.15 mg/kg/dose BID (two preoperative doses) for
living donor recipients and 0.15 mg/kg/dose QD (one preoperative dose)
for deceased donor recipients. Postoperatively, the oral tacrolimus dose
was 0.07 mg/kg/dose BID adjusted subsequently to achieve target levels
of 12–14 ng/ml from day 0 to 7, 10–12 ng/ml from week 2 to 8, 7–10
ng/ml from week 9 to 12 and 5–7 ng/ml after 12 weeks. Evidence of
tacrolimus toxicity on any protocol biopsy resulted in a further lowering
of the tacrolimus target level to 4–6 ng/ml before the first year and 3–5
ng/ml after the first year posttransplantation. Intravenous MMF was dosed
at 1200 mg/m2/day in two divided doses preoperatively and for the first
48 h postoperatively. Oral MMF was dosed at 600–900 mg/m2/day in two
divided doses; the dose range allowed for dose titration according to tolera-
bility and side effects of MMF. This regimen was used in both the SF and the
SB arm.
Extended daclizumab (Zenapax R©, Hoffman-La Roche, Basel, Switzerland)
dosing was the investigational product for evaluation (BB-IND-10127 held
by MS from 1999 to 2004, and NIAID from 2004 till date). The dosing for
daclizumab for the SF arm was 2 mg/kg pretransplant followed by 1 mg/kg
at weeks 2, 4, 6, 8, 11 and months 4, 5 and 6. For the SB arm, daclizumab
was given at a dose of 1 mg/kg peri-operatively and then at week 2, 4, 6 and
8. In the SB arm, MMF and tacrolimus were dosed in a manner similar to the
SF protocol. In the SB arm, prednisone 10 mg/kg was given peri-operatively
followed by 2 mg/kg/day in subjects weighing <40 kg and 1.5 mg/kg/day in
subjects weighing >40 kg. The prednisone dosing was tapered as follows:
by the end of weeks 1, 2, 4, 6, 12 and 16, dosages were 0.5, 0.4, 0.3, 0.2,
0.15 and 0.1 mg/kg/day, respectively. The prednisone dose of 0.1 mg/kg
was achieved by no later than 6 months posttransplant.
Concomitant medications included intravenous gancyclovir or oral valgan-
cyclovir for anti-viral prophylaxis for minimum the first 100 days posttrans-
plantation and trimethoprim/sulfamethoxazole (Septra R©) for pneumocystis
prophylaxis for a minimum first 6 months posttransplantation.
All patients had protocol renal biopsies planned at 0, 6, 12 and 24 months
after transplantation. Biopsies for indication were performed at times of
graft dysfunction. Clinical acute rejection was defined as an acute rejection
episode, associated with graft dysfunction, based on a greater than 10%
rise in serum creatinine from baseline values, and confirmed through central
pathological reading of the biopsies according to the updated Banff classi-
fication (27,28). Clinical T cell mediated rejection was treated with three
pulses of intravenous corticosteroid (10 mg/kg) with the immediate return
to SF maintenance therapy in the SF arm. Vascular rejection was treated
with thymoglobulin with steroid premedication (1 mg/kg/dose). Subclini-
cal borderline Banff grade rejection was treated with immunosuppression
intensification without steroid pulsing. There was no fixed protocol for treat-
ment of steroid-resistant rejection, which was treated per center protocol.
Guidelines for removing individual subjects from study therapy were biopsy
proven acute cell mediated rejection episode not responsive to treatment,
biopsy proven acute rejection episode recurring within 3 months, delayed
graft function (DGF) defined as requirement for dialysis in the first week
posttransplant or <25% decline in serum creatinine in the first 72 h after
transplant.
Statistical analysis
All analyses were conducted on the intent to treat (ITT) population. The
primary efficacy endpoint of this study was the difference linear growth
between the two treatment groups at 1 year. Standardized Z-scores (SDS)
were computed following a formula ([measured height–average height in
the reference population]/standard deviation of height in the reference
population), using an age- and gender-specific calculation provided by the
NHANES III 2000 Growth Data set. From an analysis of 1 year results from
nearly 2000 NAPRTCS post-1995 transplants, the standard deviation of 1
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year change in height SDS is 0.7. Sample sizes of 65 in each study arm
achieve 81.3% power, at a 5% significance level using a two-sided test, to
detect a 0.5 standard deviation shift. A sensitivity analysis of the primary
efficacy endpoint was conducted, with comparisons between the last ob-
servation carried forward (LOCF) method versus other approaches including
differing distribution assumptions and multiple imputation.
The primary safety endpoint was the rate at 12 months of biopsy proven
acute rejection according to the updated Banff classification (27,28). Sample
sizes of 65 from the steroid group and 65 from the no steroid group achieve
75% power at a 5% significance level using a one-sided equivalence test
of proportions when the proportion in the steroid group is 0.15 and the
proportion in the no steroid group being tested for equivalence is 0.15
and the maximum allowable difference between these proportions that still
results in equivalence (the range of equivalence) is 0.15.The study was not
powered to definitively evaluate small differences in rejection rate.
Secondary endpoints included patient and graft survival, incidence of DGF,
acute rejection, renal function as determined by the Schwartz method
(29,30), incidence of hyperlipidemia (fasting serum triglyceride levels >140
mg/dl and/or fasting serum cholesterol levels >190 mg/dl), hypertension
(defined as present based on actual values of systolic or diastolic blood
pressure norms for age), anemia, leucopenia, infectious complications, sur-
gical complications, incidence and duration of re-hospitalizations, incidence
of biopsy proven PTLD, incidence of posttransplant diabetes mellitus (fast-
ing plasma glucose >126 mg/dl, based on the definition used by the Amer-
ican Diabetes Association, requiring treatment with either insulin or hypo-
glycemia agents), body disfigurement and incidence of return to steroid
therapy for subjects assigned to the SF arm.
Student’s t-test was used for continuous, and chi-square-test for categorical
variables when comparing the two treatment groups. When sample sizes
were small, nonparametric tests such as the Wilcoxon test for continuous
variables or Fisher’s exact test for two-way classification tables, respec-
tively, were used for hypothesis testing. Mixed model repeated measures
were used for analyses of continuous outcomes, such as change in growth
from baseline and blood pressure levels. The Restricted Maximum Like-
lihood (REML) method, as implemented in SAS PROC MIXED, was used
for variance estimation to account for repeated observations. The Kaplan–
Meier method was used for time-to-event analyses and log-rank test was
used to test differences in the median time-to-event. Data values were re-
ported as mean ± standard deviation for patient demographic information,
and were reported as mean ± standard error of the mean for the clinical
outcomes. p-Values ≤0.05 were considered statistically significant. All sta-




One hundred thirty subjects were enrolled for randomiza-
tion into either study arm from 12 different US pediatric
transplant programs. More SB patients were enrolled in
two centers, resulting in unequal final numbers in the two
arms, with 60 in the SF and 70 in the SB groups. De-
mographic characteristics (Table 1) were similar between
the two treatment groups. A quarter of the patients were
African-Americans in both groups. Approximately 60% of
recipients received deceased donor grafts (Table 1). Of the
total patients enrolled, 10 patients in the SF arm and 18
patients in the SB arm were dropped from the study. The
causes of termination were graft failure in seven cases,
investigator’s decision in three cases, loss to follow-up in
four cases, relocation in eight cases, protocol deviation in
two cases, consent withdrawal in three cases and another
reason in one case. None of the grafts was lost due to
DGF, defined as requirement of dialysis in the first post-
transplant week. DGF occurred in 11.7% (7/60) of patients
in SF group and in 10.0% (7/70) of patients in the SB group
(p = 0.784), but was not a reason for protocol break in
either arm. Five patients from the SF study group (8.3%)
switched to steroids. They remained in the study but were
transitioned to “reduced follow-up”. In total, 134 indication
biopsies of adequate quality were performed, 69 in the SB
study arm and 65 in the SF arm.
Primary efficacy endpoint: growth
For the overall study IIT population there was no significant
difference between the SF and SB groups with respect to
linear growth at three years posttransplant (change in stan-
dardized height Z-score –0.99 ± 2.20 in SF vs. –0.93 ±
1.11 in SB; p = 0.786). There was also no significant dif-
ference for linear growth at three years follow-up overall
for a combined cohort of all children with growth poten-
tial defined as females <16 years and males <18 years
(change in standardized height Z-score –0.92 ± 2.29 in SF
vs. –0.96 ± 1.16 in SB; p = 0.732). Within the African-
American subgroup, the increase in Z-score was 0.38 (SE
0.148) in the SF group and 0.25 (SE 0.124) in the SB group
(p = 0.518).
There were 27 children <5 years of age (11 in the SF and 16
in the SB arms). This group showed a numerically greater
growth rate at 3 years posttransplantation (change in stan-
dardized height Z –0.43 ± 1.15 vs. –1.07 ± 1.14; p = 0.844
with LOCF analysis), and when this was adjusted for base-
line height, the treatment effect was significant (mixed
model group effect p = 0.019; Figure 1A). Change in height
Z-score from baseline tended to be different between the
SF and the SB arm in the first months after transplanta-
tion, but this effect was lost by 1 year after transplantation
(Wilcoxon p = 0.79 at 1 year and p = 0.84 at 3 years after
transplantation) (Figure 2).
Primary safety endpoint: acute rejection
Acute rejection in for-cause biopsies: By 1 year af-
ter transplantation, biopsy-proven acute clinical rejection
occurred in 13.3% of SF versus 11.4% of SB patients
(p = 0.74) (Table 2). Also when borderline changes were
included, the incidence of rejection was comparable be-
tween both study groups (20.0% in SF vs. 18.6% in SB;
p = 0.84) by 1 year after transplantation. Over the 3 years
of follow-up, there was no significant difference in the rate
of biopsy-proven acute clinical T cell mediated rejection
(16.7% in SF vs. 17.1% in SB; p = 0.94). Also when bor-
derline changes were included, no difference was noted
at 3 years after transplantation (26.7% in SF vs. 28.6%
in SB; p = 0.81). There was also no difference in the
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Table 1: Baseline patient characteristics
Baseline patient characteristics Steroid-free Steroid-based p-Value
N 60 70
Recipient
Mean age (year) (median; range) 11.8 ± 5.4 (12.7; 1.5–19.9) 11.9 ± 6.1 (11.9; 1.0–20.3) 0.93
Infant: ≤ 5 year old (%) 18.3% 21.4% 0.66
5–12 years old (%) 30.0% 22.9% 0.36
>12 years old (%) 51.7% 55.7% 0.64
Mean age (year) males 11.3 ± 5.5 12.1 ± 6.6 0.55
Mean age (year) females 12.9 ± 5.2 11.6 ± 5.4 0.42
Gender: females (%) 33% 40% 0.43
Mean height (cm) (median; range) 137.6 ± 26.5 (143; 75.8–183) 136.0 ± 33.3 (143; 71.0–183) 0.77
Height Z-score –1.2 ± 1.4 –1.3 ± 1.3 0.70
Mean weight (kg) (median; range) 40.2 ± 18.9 (40.6; 10–85) 40.7 ± 22.9 (41.3; 8.8–113) 0.86
Mean BMI (kg/m2) 19.9 ± 4.1 20.0 ± 4.1 0.90
Mean BSA (m2) 1.2 ± 0.4 1.2 ± 0.5 1.00
Race (1, 2, 3, 4) † 55%, 25%, 8%, 12% 50%, 27%, 4%, 19% 0.56
CMV D+R- 46.7% 42.9% 0.66
EBV D+R- 13.3% 11.4% 0.74
Transfusions 0, 1–5, >5, unknown (%) 48.3, 40.0%, 6.7%, 5.0% 64.3%, 24.3%, 8.6%, 2.9% 0.08
Dialysis mode pretransplant (none,
hemodialysis, peritoneal dialysis,
both)
20%, 36.7%, 20.0%, 23.3% 14.3%, 41.4%, 21.4%, 22.9% 0.39
Cold ischaemia time (min) 705.1 ± 479.1 716.6 ± 416.5 0.90
Cause of ESRD (1, 2, 3, 4, 5, 6, 7, 8)∗ (8%, 3%, 18%, 2%, 12%,
15%, 3%, 38%)
(10%, 1%, 16%, 11%, 11%,
9%, 9%, 33%)
0.33
Mean eGFR (ml/min 1.73 m2) 14.2 ± 9.6 13.8 ± 8.1 0.81
Mean hematocrit (%) 33.9 ± 6.4 34.4 ± 6.8 0.71
Mean white cell count (ul) 8.7 ± 3.9 7.8 ± 2.8 0.12
Mean serum cholesterol (mg/dl) 160.8 ± 40.2 148.5 ± 40.9 0.12
Mean serum triglyceride (mg/dl) 177.1 ± 89.7 164.8 ± 109.9 0.53
Mean systolic blood pressure
(mmHg)
126.4 ± 19.4 122.7 ± 20.3 0.30
Mean diastolic blood pressure
(mmHg)
74.7 ± 15.9 72.1 ± 15.4 0.35
Donor
Mean donor age (median; range) 29.1 ± 10.1 (28.5; 2–47) 27.4 ± 10.0 (26.5; 5–54) 0.34
Gender: females (%) 47% 40% 0.44
Donor type (LRD) 40% 34% 0.59
Mean HLA match LRD 2.5 ± 1.9 1.9 ± 1.4 0.06
Mean HLA match DD 0.6 ± 0.9 0.7 ± 0.8 0.85
†1 = White; 2 = Black/African American; 3 = Asian; 4 = Others.
∗1 = glomerulonephritis; 2 = polycystic kidney disease; 3 = dysplasia; 4 = reflux nephropathy; 5 = obstructive uropathy; 6 = FSGS;
7 = congenital nephrotic syndrome; 8 = others.
incidence of steroid-resistant acute rejection (19.0% of
acute rejections in SF vs. 25.8% in SB; p = 0.74). Antibody-
mediated rejection was seen in only four indication biop-
sies from three different patients (two in the SF arm and
one in the SB arm). There was no difference in the num-
ber of subjects who had recurrent acute rejection within
3 months (0% of acute rejections in SF vs. 25.0% [n =
2] in SB; p = 0.1). There was no difference in the time
to first acute rejection between groups (detailed histo-
logical analysis in accompanying submission by Naesens
et al. (31))
Acute rejection in protocol biopsies
Central pathological reading of the 256 posttransplant pro-
tocol biopsies, performed in patients with stable graft
function (47, 35 and 33 at respectively 6, 12 and 24 months
after transplantation in the SF treatment arm, and 53, 46
and 42 in the SB treatment arm), showed that the risk for
subclinical T cell-mediated rejection was similar between
both treatment arms at each protocol biopsy time point
(Table 2). There was also no significantly increased risk
for borderline changes in protocol biopsies. The incidence
of subclinical antibody-mediated rejection was too low to
allow for statistical analysis.
This study was not powered to examine small differences
in rejection rates in patient subgroups. Nevertheless, since
the African-American group has traditionally been consid-
ered as high risk for steroid avoidance protocols, we ana-
lyzed the results in this subgroup separately. At 12 months,
2722 American Journal of Transplantation 2012; 12: 2719–2729
Steroid-Free Therapy in Pediatric Transplantation
the biopsy proven AR rates were 13.3% (SF group; two
episodes in 15 subjects) versus 31.1% (SB group, six
episodes in 19 subjects, p = 0.26). At 36 months, the rates
were almost identical (BPAR rate 33.3% in SB, 5 episodes
in 15 subjects vs. 36.8% in SF, 7 episodes in 19 subjects,
p = 1.0).
Secondary endpoints
Patient and graft survival : Patient survival was 100% in
both arms at 3 years; graft survival was 95% in the SF and
90% in the SB arms (p = 0.30) at 3 years follow-up (Table
2). The causes of the seven graft losses in SB group were
acute rejection (n = 2), chronic rejection (n = 3), medication
nonadherence (n = 1) and recurrence of original kidney
disease (n = 1). The three graft losses in the SF arm were
due to medication nonadherence (n = 2) and recurrence of
original kidney disease (n = 1).
Graft function
Between the two groups, there were no significant differ-
ences in graft function based on eGFR (ml/min/1.73 m2) by
the Schwartz formula (29, 30) for ITT SF and SB population
(100.5 ± 4.8 for SF vs. 102.3 ± 4.5 for SB at 1 year; 93.7 ±
4.9 for SF vs. 95.9 ± 4.6 for SB at 2 years; 83.0 ± 5.0 for SF
vs. 80.8 ± 4.9 for SB at 3 years; mixed model group effect
p = 0.446) (Figure 1B). In addition, there was no significant
difference regardless of whether or not the patients had
an AR episode (101.5 ± 4.8 for SF vs. 102.3 ± 4.5 for SB
at 1 year; 93.7 ± 4.9 for SF vs. 95.9 ± 4.6 for SB at 2 years;
83.0 ± 5.0 for SF vs. 80.8 ± 4.9 for SB at 3 years; mixed
model group effect p = 0.64). DGF occurred in 6.7% of
patients in the SF group versus 1.4% of patients in the SB
group (p = 0.18).
Diabetes mellitus
There was no statistical difference in posttransplant dia-
betes between the groups at the 3 years posttransplanta-
tion (1.7% in SF vs. 5.7% in SB; p = 0.373).
Body mass index and body disfigurement
There was no significant difference in body mass index
between two groups at the 3 years posttransplantation
(26.6 ± 5.1 vs. 24.1 ± 6.6; p = 0.17). Cushingoid facies
was observed significantly more frequently at 3 years in
the SB arm compared to the SF arm (respectively in 34%
in SB vs. 2.1% in SF; p < 0.001), although it is important
to note that this is a subjective parameter and the current
study was not conducted in a double-blind fashion.
Hypertension and hyperlipidemia
Standardized systolic blood pressure was significantly
lower in SF versus SB over the first 3 years after trans-
plantation (mixed model group effect p = 0.017) and there
was a nonsignificant trend toward lower diastolic BP in SF
versus SB (mixed model group effect p = 0.08) (Figures
1C and 1D). The SF group had a significantly lower total
cholesterol level than SB group (mixed model group effect
p = 0.034). The overall treatment effect for triglyceride level
was not significant (p = 0.212) (Figures 1E and 1F).
Infections, malignancies and hospitalizations
There was no increase in the number of hospitalizations in
the SF group versus the SB group. There was no difference
in the time to first re-hospitalization (p = 0.346 log-rank
test), and 80% of SF and 86% of SB patients had one
or more hospitalizations posttransplantation. There was no
PTLD in both groups. Five SF subjects (8.3%) and six SB
subjects (8.6%) had BK viremia (p = 0.96). Of these, BK
nephritis occurred in three patients in the SB group versus
one in the SF group (p = 0.62). Eleven SF subjects and 12
SB subjects reported having Cytomegalovirus infection or
viremia (p = 0.26). Other relevant adverse events are listed
in Table 3.
Discussion
This study reports the first 3-year randomized, prospec-
tive, multicenter trial in pediatric kidney transplantation
that tests the safety and efficacy of a complete steroid
avoidance protocol. The study cohorts represent a selected
group of unsensitized recipients of first transplants, with-
out prolonged cold ischemia times. This is also the first
pediatric clinical trial that compares two different treat-
ment protocols with detailed reporting on the subclinical
occurrence of acute rejection and progression of chronic
injury, assessed by serial protocol biopsies at prespecified
intervals. The histological substudy, presented separately
from the current manuscript (31), showed that subclinical
progression of chronic histological damage and subclini-
cal inflammation are not different between both treatment
arms.
The excellent patient and graft survival, the absence of
any increase in acute rejection, viral and bacterial infec-
tions, and the absence of PTLD support earlier single-
center study results (4,24,25) on the safety of complete
steroid avoidance. The low infection and malignancy rates
are particularly important as there was a double total dose
of daclizumab administered for 4 months longer in the SF
than the SB protocol, with equivalent dosing for tacrolimus
and MMF in the two treatment arms. Furthermore, given
some recent concerns of hypersensitivity with chimeric
monoclonal interleukin 2 receptor antibody (basiliximab)
infusions (32,33), it is important to note that there were
no infusion-related adverse events with the fully human-
ized daclizumab in either treatment arm. The results of the
current study can, however, not be generalized, and as da-
clizumab has been withdrawn from the market, it will be
necessary to separately evaluate the safety and efficacy
of basiliximab for induction in SF immunosuppressive reg-
imens in pediatric kidney transplantation.
The incidence of clinical and subclinical T cell mediated
rejection was similar in the two treatment arms. This is
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Figure 1: Estimated group mean standardized change in growth (Z-score) among infants and young children (A), mean eGFR level
(by Schwartz method) (B), mean diastolic (C) and systolic (D) blood pressure levels and serum cholesterol (E) and triglyceride (F)
levels from transplantation up to three year. Values are estimated group means ± Standard Error (SE) from a repeated measure mixed
model with treatment and time (in study month) as main effects, and treatment by time interaction. The p-value for overall treatment
effect in each analysis is given.
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Figure 2: Change in height Z-score from baseline amongst infants and young children < 5 years of age. Change in height Z-score
from baseline tended to be different between the SF and the SB arm in the first months after transplantation, but this effect was
lost by 1 year after transplantation (Wilcoxon p = 0.79 at 1 year and p = 0.84 at 3 years after transplantation).
in contradistinction to studies in adults, where there was
a higher incidence of acute rejection in steroid avoidance
and withdrawal (19). None of the clinical acute rejections
in the SF arm recurred within 3 months of the initial re-
jection episode, while in the SB arm 25% of the acute
rejections recurred within 3 months of the initial rejection
episode. Although this finding reached only borderline sta-
tistical significance, it possibly suggests that the mecha-
nisms of immunological escape during rejection may be
different depending on whether or not the patient is be-
ing treated with steroids. Though this clinical study cannot
dissect the specific impact of extended dose daclizumab
Table 2: Secondary endpoints
Secondary endpoints Steroid-free treatment group Steroid-based treatment group p-Value
Number of patients 60 70
Patient survival by 3 years 60/60 (100%) 70/70 (100%) NA
Graft survival by 3 years 57/60 (95.0%) 63/70 (90.0%) 0.30
Delayed graft function 4/60 (6.7%) 1/70 (1.4%) 0.18
Graft function (Schwartz eGFR, mL/min/1.73 m2)
At 1 year (mean ± SD; median) 100 ± 28.8; 102 (n = 56) 103 ± 33.9; 101 (n = 63) 0.90
At 3 years (mean ± SD; median) 86.3 ± 30.5; 89 (n = 49) 83.9 ± 28.5; 85 (n = 48) 0.72
Acute T cell-mediated rejection in indication biopsies (graft dysfunction)
Cumulative prevalence at 1 year 8/60 (13.3%) 8/70 (11.4%) 0.74
Cumulative prevalence at 3 years 10/60 (16.7%) 12/70 (17.1%) 0.94
Borderline changes or T cell-mediated rejection in indication biopsies (graft dysfunction)
Cumulative prevalence at 1 year 12/60 (20.0%) 13/70 (18.6%) 0.84
Cumulative prevalence at 3 years 16/60 (26.7%) 20/70 (28.6%) 0.81
Acute T cell-mediated rejection in protocol biopsies (stable graft function)
At 6 months 5/47 (10.6%) 6/53 (11.3%) 0.91
At 12 months 0/35 (0.0%) 2/46 (4.3%) 0.21
At 24 months 0/33 (0.0%) 2/42 (4.8%) 0.20
Borderline changes in protocol biopsies (stable graft function)
At 6 months 4/47 (8.5%) 5/53 (9.4%) 0.87
At 12 months 6/35 (17.1%) 2/46 (4.3%) 0.06
At 24 months 4/33 (12.1%) 1/42 (2.4%) 0.09
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Table 3: Overall incidence of serious and nonserious adverse events regardless of relationship to study medication
Steroid-free Steroid-based
Nonserious adverse events treatment group treatment group
Number of subjects with at least one nonserious adverse event 56/60 (93.3%) 64 (91.4%)
Blood and lymphatic system disorders 37 (66.1%) 38 (59.4%)
Anemia 25 (44.6%) 21 (32.8%)
Neutropenia 24 (42.9%) 21 (32.8%)
Leukopenia 14 (25.0%) 12 (18.8%)
Gastrointestinal disorders 29 (51.8%) 27 (42.2%)
Diarrhea 18 (32.1%) 19 (29.7%)
Vomiting 11 (19.6%) 8 (12.5%)
Nausea 6 (10.7%) 5 (7.8%)
Stomatitis 2 (3.6%) 0 (0.0%)
Infections and infestations 44 (78.6%) 47 (73.4%)
Urinary tract infection 14 (25.0%) 20 (31.3%)
Upper respiratory tract infection∗ 20 (35.7%) 10 (15.6%)
Otitis media 9 (16.1%) 8 (12.5%)
CMV infection 8 (14.3%) 6 (9.4%)
EBV infection 6 (10.7%) 4 (6.3%)
Metabolism and nutrition disorders 29 (51.8%) 36 (56.3%)
Hyperkalemia 12 (21.4%) 10 (15.6%)
Hypophosphatemia 10 (17.9%) 12 (18.8%)
Hypomagnesemia 6 (10.7%) 6 (9.4%)
Metabolic acidosis 5 (8.9%) 3 (4.7%)
Hyperglycemia 1 (1.8%) 5 (7.8%)
Hyperlipidemia∗ 0 (0.0%) 5 (7.8%)
Vascular disorders 19 (33.9%) 26 (40.6%)
Hypertension 14 (25.0%) 19 (29.7%)
Musculoskeletal and connective tissue disorders 7 (12.5%) 9 (14.1%)
Skin and subcutaneous tissue disorders 5 (8.9%) 14 (21.9%)
Nervous system disorders 6 (10.7%) 9 (14.1%)
Serious adverse events
Number of subjects with at least one serious adverse event 52 (86.7%) 60 (85.7%)
Blood and lymphatic system disorders 2 (3.8%) 3 (5.0%)
Anemia 0 (0.0%) 1 (1.7%)
Neutropenia 0 (0.0%) 2 (3.3%)
Gastrointestinal disorders 9 (17.3%) 9 (15.0%)
Diarrhea 3 (5.8%) 3 (5.0%)
Peritonitis 0 (0.0%) 2 (3.3%)
Infections and infestations 25 (48.1%) 28 (46.7%)
Pyelonephritis 7 (13.5%) 8 (13.3%)
Urinary tract infection 7 (13.5%) 7 (11.7%)
Gastroenteritis 3 (5.8%) 8 (13.3%)
CMV infection 1 (1.9%) 3 (5.0%)
Pneumonia 3 (5.8%) 4 (6.7%)
Herpes zoster 1 (1.9%) 2 (3.3%)
Metabolism and nutrition disorders 7 (13.5%) 13 (21.7%)
Dehydration 3 (5.8%) 7 (11.7%)
Hyperkalemia 3 (5.8%) 2 (3.3%)
Posttransplant diabetes mellitus 1 (1.7%) 4 (5.7%)
Vascular disorders 4 (7.7%) 7 (11.7%)
Hypertension 1 (1.9%) 3 (5.0%)
Renal and urinary disorders 12 (23.1%) 13 (21.7%)
Musculoskeletal and connective tissue disorders 1 (1.9%) 0 (0.0%)
Skin and subcutaneous tissue disorders 1 (1.9%) 1 (1.7%)
Nervous system disorders 3 (5.8%) 2 (3.3%)
Posttransplant lymphoproliferative disorder 0 (0.0%) 0 (0.0%)
Note. Presented are adverse events with an occurrence of ≥10% of patients in either treatment group or with a significant difference
between groups or of clinical importance. Excluded are adverse events related to the transplanted organ, abnormal laboratory values and
complications of surgery. ∗p-Value <0.05.
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from the impact of complete steroid avoidance, it is pos-
sible that the prolonged use of daclizumab was a key im-
munomodulatory agent that diminished the risk of acute
rejection recurrence. On the other hand, evaluating liter-
ature on the effect of chronic steroids in animal and hu-
man models of organ transplantation (5,8–11,34,35), we
can hypothesize that the higher rejection recurrence rate
in the SB arm may reflect an element of steroid depen-
dence. The clinical significance of the numerically higher
rate of borderline changes in protocol biopsies at 12 and
24 months posttransplantation is yet unclear (36), and was
counterbalanced by numerically higher number of patients
that developed acute T cell-mediated rejection after one
year in the SB group.
Another safety parameter is the absence of any negative
impact of steroid avoidance on the incidence of DGF. There
was some concern whether ischemia reperfusion injury
at the time of engraftment would require peri-operative
steroid exposure to facilitate immediate graft function (37).
Our study suggests that in a low-risk immunologic recipi-
ent of a first graft with cold ischemia time of <20 h, peri-
operative steroids may not be required (38). There are
currently no data suggesting the best course for steroid
avoidance or withdrawal in the high risk pediatric setting.
Importantly, our study found that graft function was equiv-
alent in the two arms at the end of three posttransplant
years.
In terms of efficacy, the primary endpoint, i.e. linear growth
in the overall group, was not different between both treat-
ment arms. However, when linear growth was further strat-
ified for age, there was a significantly greater growth rate
for infants and small children under 5 years in the SF group
compared to the SB treatment arm. This confirms previous
single-center observations (24,25). The similarity in growth
between the SF and SB groups for the study population as
a whole can be explained by the wide recipient age range
in this study. Specifically, our study had a high percentage
of adolescent transplant recipients (n = 63), as would be
expected in a cross-section of kidney transplants in the
US population as a whole (39). In addition, the prednisone
dose in the SB group was low (0.1 mg/kg or less by 6
months) and perhaps blunted the differences in growth
usually seen with higher doses of steroids (see below).
Finally, it is possible that the effects of steroid avoidance in
the smallest recipients persist many years later, as a pre-
vious observation noted unprecedented catch-up growth
rates, greater than the growth velocity in normal healthy
age and gender-matched controls, after 4 years posttrans-
plantation (25).
Our 36 month follow up results substantiate our early 12
month results (40) and the 6 month results of the Euro-
pean TWIST study (41). In the TWIST study, the mean
treatment group difference in linear height Z-score was
0.13 (p < 0.005) in children under 5 years age, 0.21 in pre-
pubertal (p = 0.009) and 0.05 in pubertal children (p = ns).
It is, however, interesting that the dose of steroids used in
the TWIST SB arm at 6 months (<0.3 mg/kg) was always
higher than they were in our SB patients. When converting
mg/m2 to mg/kg, it turns out that patients in the TWIST re-
ceived doses of steroids that were different by a factor of
0.5–3. This is particularly true in patients above the weight
of 20 kg (data not shown).
Our study also addresses an additional important question,
whether steroid avoidance immunosuppression is safe in
African-American recipients. African-American recipients
generally have worse outcomes after kidney transplanta-
tion. In particular, this group exhibits higher rates of acute
rejection and earlier graft loss, especially in earlier steroid
withdrawal studies (12). The proportion of African Amer-
icans enrolled in adult recipient studies of steroid avoid-
ance (14,42,43) has been too small to judge if these pa-
tients would be at risk with a steroid avoidance strategy.
Single center reported series also have a small percent-
age of African-American recipients (25,44). However, in
the current multi-center prospective trial, African-American
patients did equally well in terms of acute rejection as
other groups with steroid avoidance and did not exhibit
any untoward effects, although it should be noted that
the number of African-American patients in the current
study was still relatively low (n = 34, 26.1%) to draw firm
conclusions.
In conclusion, complete steroid avoidance, combined with
effective induction, tacrolimus and mycophenolate mofetil,
provides a new therapeutic standard for safe and effective
immunosuppression for renal transplantation of low-risk
children with end stage renal disease.
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